Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 9Gastrointestinal 2Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1CNS 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Cyclophosphamide 261fludarabine phosphate 233Azacitidine 182fludarabine 181Busulfan 176Cytarabine 155Imatinib Mesylate 152Mycophenolic Acid 148Tacrolimus 146Whole-Body Irradiation 142Peripheral Blood Stem Cell Transplantation 140Cyclosporine 110Antilymphocyte Serum 108Melphalan 107Methotrexate 105Filgrastim 101Decitabine 98nilotinib 94venetoclax 79ruxolitinib 79Dasatinib 68Granulocyte Colony-Stimulating Factor 66Stem Cell Transplantation 63Thiotepa 60Radiotherapy 60thymoglobulin 52Specimen Handling 49Etoposide 49Clofarabine 46Cord Blood Stem Cell Transplantation 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peptides × Myeloid × Clear all
NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
10 enrolled 7 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡